BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22892435)

  • 1. Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: a population-based analysis.
    Mishra MV; Shen X; Den RB; Champ CE; Trabulsi EJ; Lallas CD; Gomella LG; Dicker AP; Showalter TN
    Am J Clin Oncol; 2013 Dec; 36(6):606-11. PubMed ID: 22892435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who bears the greatest burden of aggressive treatment of indolent prostate cancer?
    Mahal BA; Cooperberg MR; Aizer AA; Ziehr DR; Hyatt AS; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Orio PF; Trinh QD; Nguyen PL
    Am J Med; 2015 Jun; 128(6):609-16. PubMed ID: 25644324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT
    J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
    Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
    J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
    Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marital status and prostate cancer outcomes.
    Tyson MD; Andrews PE; Etzioni DA; Ferrigni RG; Humphreys MR; Swanson SK; Castle EK
    Can J Urol; 2013 Apr; 20(2):6702-6. PubMed ID: 23587510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate brachytherapy: a descriptive analysis from CaPSURE.
    Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
    Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.
    Varkarakis J; Pinggera GM; Sebe P; Berger A; Bartsch G; Horninger W
    Urology; 2004 Feb; 63(2):337-41. PubMed ID: 14972485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study.
    Abdollah F; Sun M; Thuret R; Abdo A; Morgan M; Jeldres C; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Cancer Causes Control; 2011 Aug; 22(8):1085-95. PubMed ID: 21643929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
    Dall'era MA; Hosang N; Konety B; Cowan JE; Carroll PR
    J Urol; 2009 Apr; 181(4):1622-7; discussion 1627. PubMed ID: 19230923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
    J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment.
    Yeboa DN; Guzzo T; Mitra N; Christodouleas JP; Haas NB; Vapiwala N; Armstrong K; Bekelman JE
    Urology; 2011 Nov; 78(5):1107-13. PubMed ID: 21943872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.
    Scosyrev E; Wu G; Mohile S; Messing EM
    Cancer; 2012 Dec; 118(23):5768-76. PubMed ID: 22847578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.